Connect with us
European Gaming Congress 2024

Artificial Intelligence

Automation in Biopharma Industry Market is Projected to Grow at a CAGR of 5.7% by 2033: Visiongain

Published

on

As per the report by Visiongain, the Global Automation in Biopharma Industry Market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033. 

Visiongain has published a new report entitled Automation in Biopharma Industry 2023-2033. Forecasts by Technology (Automation Technology, Digitization Technology), by Application (Clinical Phase, Drug Discovery Phase, Production Phase), by Component (Automation Hardware, Automation Software, Services Project Phase, Services Operation Phase), by Automation Technology (Supervisory Control and Data Acquisition (SCADA), Distributed Control Systems (DCS), Programmable Logic Controllers (PLC), Manufacturing Execution System (MES), Human-machine Interface (HMI), Advanced Process Control (APC), Enterprise Resource Planning (ERP), Laboratory Information Management System (LIMS), Customer Relationship Management (CRM), Corrective and Preventive Actions (CAPA), Other Automation Technologies)), by Digitization Technology (Internet of things (IoT), Artificial Intelligence (AI), Digital Twin Technology, Augmented Reality (AR) and Virtual Reality (VR), Predictive Analytics, Cloud Computing)) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. 

Automation Can Help Reduce the Risk of Contamination 

Biopharma automation is a way to incorporate advanced technologies and automated systems into the manufacturing process to improve efficiency, accuracy, and reliability. By utilizing biopharma automation, drug production can see improvements in both consistency and quality. 

Biopharma automation can improve consistency and quality in several ways. Precision is one such improvement, as automated systems can perform tasks with a higher degree of accuracy than humans. This can reduce the risk of errors and inconsistencies that can impact drug quality, ensuring that the final product meets the exact specifications required for its intended use. 

Advertisement

Increased efficiency is another advantage of biopharma automation, as automated systems can perform tasks much faster than humans. This can reduce the time it takes to produce a drug, enabling companies to keep up with growing demand for their products and ensure that drugs are produced in a timely manner. 

Automation can also enhance process control, which is crucial for improving consistency and quality. Automated systems can monitor and control the manufacturing process more closely than humans, ensuring that critical process parameters are maintained within a narrow range. This can reduce variability in the production process, resulting in more consistent product quality. Finally, biopharma automation can help reduce the risk of contamination, a major concern in the industry. By minimizing the need for human intervention, automation can reduce the risk of contamination from human operators and improve product purity. 

Download Exclusive Sample of Report 

https://www.visiongain.com/report/automation-biopharma-industry-market-2023/#download_sampe_div

How has COVID-19 had a Significant Impact on the Automation in Biopharma Industry Market? 

Advertisement

COVID-19 has had a significant impact on many industries, including the automation in biopharma industry market. While the pandemic has increased the demand for vaccines and therapeutics, it has also caused disruptions in the supply chain and manufacturing processes. 

The COVID-19 pandemic has posed significant challenges for the automation in biopharma industry market, primarily due to the disruption of global supply chains. The implementation of lockdowns and travel restrictions in several countries has made it difficult to transport raw materials and finished products, resulting in delays and shortages. 

Another challenge posed by the pandemic is the shutdown of several manufacturing facilities due to COVID-19 outbreaks among workers. This has resulted in reduced production capacity and further delays in the supply chain. Moreover, the pandemic has caused a reduction in investment in the automation in biopharma industry market, as many companies have redirected their resources towards developing COVID-19 vaccines and therapeutics, leading to a decrease in investment in other areas. 

Finally, the pandemic has also resulted in a reduction in the number of clinical trials being conducted, which has had a negative impact on the demand for biopharma automation solutions. Clinical trials are a key driver of demand for automation solutions as they require large quantities of high-quality drugs to be produced quickly and accurately. 

How will this Report Benefit you? 

Advertisement

Visiongain’s 396-page report provides 134 tables and 205 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global automation in biopharma industry market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Automation in Biopharma Industry. Get financial analysis of the overall market and different segments including technology, application, component, automation technology, digitization technology, and company size and capture higher market share. We believe that there are strong opportunities in this fast-growing automation in biopharma industry market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company. 

What are the Current Market Drivers? 

Technological Advancements to Improve Product Safety 

For pharmaceutical manufacturers, new medicine formulations and delivery methods also pose safety issues. The DTC channel, for instance, “handles packages far more often than those transported through typical bulk channels, resulting in overall rougher handling and higher possibility of packaging or product damage. The popularity of injectables has also increased the focus on sterility, as clean production is vitally essential given the nature of these medications and injection delivery. Automated solutions, especially those aided by artificial intelligence, can enhance product safety for both of these sorts of problems. 

Vision inspections assisted by AI can more rapidly and precisely identify package flaws. Additionally, these instruments may check for problems like glass vials flaking into liquid pharmaceuticals, which is a problem with several injectable prescriptions. Overall limiting human involvement in manufacturing can enhance hygienic conditions, and as washdown robots become more prevalent, these devices can enhance sterility and safety all along the pharmaceutical production line. 

Advertisement

Increasing Need for Machine Flexibility 

75 percent of pharmaceutical organisations revealed that they want to use automated solutions more frequently. This is mostly being driven by the trend toward injectables and more individualised drugs, in addition to manpower shortages. Production lines for pharmaceuticals are challenged by customised dosages and things like pre-filled syringes. As a result, manufacturers are searching for equipment that can handle the greater range of formats generated in smaller batch sizes while still reducing downtime. Machines must be adaptable and able to handle frequent changeovers due to the greater variety of formats and sizes, and automated solutions make these procedures easier. In addition, with the explosion of direct-to-consumer (DTC) shipping brought on by the recent expansion of e-commerce, packaging and labelling must change in order to get pharmaceuticals to patients safely and effectively. 

Download Exclusive Sample of Report 

https://www.visiongain.com/report/automation-biopharma-industry-market-2023/#download_sampe_div

Where are the Market Opportunities? 

Advertisement

Robotics is Valuable For Biopharma Operations 

Robotics is becoming increasingly important to operations, but only when used to improve process efficiency, speed, and quality. Rapidly evolving robotics are finding a genuine position on the battlefield. Robotics are gaining recognition as a valuable asset to operations in the biopharmaceutical industry. By integrating advanced robotic systems, biopharma companies can streamline and optimize their manufacturing processes, resulting in increased productivity and improved product quality. 

One of the main benefits of incorporating robotics in biopharma operations is the ability to perform tasks with a high level of precision and accuracy. Robots can perform repetitive tasks with consistency and speed, reducing the risk of errors and variability that can impact product quality. Additionally, robots can operate in sterile environments, reducing the risk of contamination and improving product purity. 

Another benefit of robotics in biopharma is increased efficiency. Robotic systems can operate continuously and around the clock, reducing manufacturing time and increasing output. This can lead to significant cost savings and allow for faster production of drugs. 

Research and Development Through Automation of Lab Processes 

Advertisement

In the biopharmaceutical industry, automation of lab processes has the potential to revolutionize research and development efforts. Automating lab processes involves using advanced technologies and systems to perform experiments and analyses, reducing the need for human intervention. This has several benefits that can help to advance research and development efforts in the industry. 

One major advantage of automating lab processes is improved accuracy and precision. Automated systems can perform tasks with a high level of accuracy, reducing the risk of errors and inconsistencies that can affect research outcomes. This can be particularly important in experiments where even small variations can have a significant impact on the results. 

Automation can also increase the speed of lab processes, allowing researchers to perform experiments and analyze data much faster than would be possible with manual processes. This can help to speed up the drug discovery and development process, allowing companies to bring new drugs to market more quickly. 

Another benefit of automation is increased efficiency. Automated systems can operate continuously, performing repetitive tasks much faster than humans. This can reduce the time and resources required to perform experiments and analyses, allowing researchers to focus on more complex tasks. 

Competitive Landscape 

Advertisement

The major players operating in the automation in biopharma industry market are ABB Robotics, Acieta LLC, ADLINK Technology Inc., AMETEK, Inc., Autodesk, Inc., Baumueller-Nuermont Corp, Emerson Electric Co., Kawasaki Robotics, PerkinElmer, Inc., RheoSense Inc., Rockwell Automation, Inc., Sartorius Stedim Biotech SA, Siemens Healthineers, TetraScience, Inc., Thermo Fisher Scientific Inc. To strengthen their position in the market, leading companies have implemented several tactics such as mergers and acquisitions, increasing investment in research and development, forming collaborations and partnerships, expanding their business into new regions, and introducing new products. 

Recent Developments 

  • In February 2023, Siemens Healthineers  and Unilabs signed a multi-year agreement worth more than €200 million (US$212.3 million). Unilabs has invested in top-tier Siemens Healthineers technology and will acquire more than 400 laboratory analyzers to improve its laboratory infrastructure and provide unrivalled service to its customers. 
  • In September 2022, PerkinElmer, Inc. introduced the Cellaca® PLX Image Cytometry System, a first-of-its-kind benchtop platform that allows researchers to assess multiple Critical Quality Attributes (CQAs) of cell samples in a single automated workflow, including cell identity, quality, and quantity.   

To access the data contained in this document please email [email protected] 

To find more Visiongain research reports on the Pharma sector, click on the following links: 

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: [email protected]

About Visiongain 

Advertisement

Visiongain is one of the fastest-growing and most innovative independent market intelligence providers around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports, which cover 10-year forecasts, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets with a lot of synergies. These markets include automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customised and syndicated market research reports offer a bespoke piece of market intelligence customised to your very own business needs. 

Contact: 

Visiongain Reports Limited 
Telephone: +44 (0) 20 7336 6100 
Email: [email protected]  
Web: www.visiongain.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

How AIoT shapes the future of mobility: Hikvision at ITS World Congress 2024

Published

on

how-aiot-shapes-the-future-of-mobility:-hikvision-at-its-world-congress-2024

HANGZHOU, China, Sept. 27, 2024 /PRNewswire/ — Hikvision made a significant impact at the ITS World Congress in Dubai with its captivating theme, “Embrace AIoT for safer, smarter, and greener mobility.” Its booth became a hub of innovation, where visitors explored AIoT solutions that are reshaping the transportation landscape, sparking deep conversations on the future of urban mobility.

Road safety revolution: harnessing AIoT for secure transportation
Hikvision’s commitment to road safety was on full display at its booth through the impressive array of AIoT solutions designed to create secure and reliable traffic environments. The company’s technology provides 24/7 traffic monitoring, ensuring continuous oversight of motor vehicles, non-motorized vehicles, pedestrians and environmental factors. This comprehensive, real-time information collection enables traffic managers to prevent accidents and enhance road safety. Among the showcased products was the 20 MP IR ANPR Checkpoint Capture Unit, renowned for its high-definition capture capabilities, bolstering traffic safety measures.
A standout innovation was the integration of advanced radar and camera technologies, ensuring uninterrupted, comprehensive detection even in adverse weather conditions. The Radar-Video Fusion Incident Detection Cameras, featured prominently in the product experience area, enable early detection and warning of potential hazards. They are particularly effective in challenging situations such as curved roads, blind spots at intersections, and obstacles beyond visual range.
Attendees also engaged with onboard monitoring products on the simulated bus, including dome network cameras, which is designed to enhance passenger safety. Driving assistance products, such as the Driver Status Monitor (DSM), were demonstrated to mitigate unsafe driving behaviors and ensure safer journeys.
Urban mobility redefined: smart traffic innovations
In the realm of smarter mobility, Hikvision showcased its multidimensional sensing technology, which integrates visible light sensors, infrared sensors, radar, and sonar. This technology expands perception capabilities, significantly improving traffic management and situational awareness. The use of AI-powered comprehensive sensing elevates incident monitoring and violation detection to unprecedented levels of accuracy and efficiency.
A major attraction was the Radar-Video Fusion TandemVu PTZ Camera, which integrates millimeter-wave radar with high-resolution cameras for extensive traffic detection and data analysis. AI-based algorithms combine these two systems to enhance target information, detecting up to 16 types of incidents. This leads to the development of a large-scale fusion model that merges spatial physical data with image semantic information. The result is ultra-long-range perception, achieving over 95% accuracy in vehicle trajectory detection. This robust system improves traffic violation management and optimizes traffic flow, significantly enhancing road efficiency.
At the simulated bus station, visitors observed how AI-assisted people counting automated the collection of passenger flow statistics at peak stop hours and bus line frequency during busy periods. Paired with smart bus stop digital signage, the solution improves bus service quality, operational efficiency, passenger experience, and overall public transport effectiveness.
Sustainable transportation: leading the charge for greener cities
Hikvision’s commitment to sustainable urban mobility was evident through its innovative green wave technology and eco-friendly checkpoint solutions. Green wave technology efficiently manages traffic flow to reduce congestion and lower carbon emissions, aligning with global sustainability goals. Visitors were particularly impressed by a case study showcasing a green wave solution implemented in Zhoushan, China. Over a stretch of 21 kilometers and 34 intersections, this main road cut travel times by 50%.
The use of DarkFighterX technology in checkpoint cameras also received significant attention. This technology senses both visible and invisible light, resulting in more accurate and realistic images. It enhances traffic violation enforcement efficiency while minimizing the need for high ambient light levels, thus reducing light pollution. The 9M DarkfightX ANPR Checkpoint Camera exemplified this dedication to environmental stewardship.
Frank Zhang, President of Hikvision MEA, remarked, “Hikvision supports sustainable urban planning by empowering traffic departments to address congestion and transportation challenges.” He further emphasized, “Our system’s openness fosters a secure and reliable platform for developing smart and green cities. Additionally, our solar technology is extensively utilized in remote areas, while our smart street lighting solutions reduce energy consumption by 20-30%, promoting intelligent urban transportation and advancing global sustainability objectives.”
Hikvision’s presence at the ITS World Congress in Dubai underscored its leadership in integrating AIoT technologies to drive safer, smarter, and greener mobility solutions. The engaging presentations and advanced product demonstrations captured significant attention from industry partners and customers, reaffirming the company’s role as a pioneer in shaping the future of urban transportation. As the world moves towards more intelligent and sustainable transportation systems, Hikvision remains at the forefront, embracing AIoT to create a safer, smarter, and greener future for all.
To find out more about Hikvision’s advanced traffic and public transport solutions, please explore the Hikvision official website.
Photo – https://mma.prnewswire.com/media/2516934/How_AIoT_shapes_future_mobility_Hikvision_ITS_World_Congress_2024.jpg

View original content:https://www.prnewswire.co.uk/news-releases/how-aiot-shapes-the-future-of-mobility-hikvision-at-its-world-congress-2024-302261298.html

Continue Reading

Artificial Intelligence

Anti-Drone Market worth $7.05 billion by 2029 – Exclusive Report by MarketsandMarkets™

Published

on

anti-drone-market-worth-$7.05-billion-by-2029-–-exclusive-report-by-marketsandmarkets™

DELRAY BEACH, Fla., Sept. 27, 2024 /PRNewswire/ — The global anti-drone market was valued at USD 2.16 billion in 2024 and is projected to reach USD 7.05 billion by 2029; it is expected to register a CAGR of 26.7% during the forecast period according to a new report by MarketsandMarkets™. Increasing government spending on counter-drone technologies, rising incidence of critical infrastructure security breaches by unauthorized drones, and surge in adoption of aerial remote sensing technologies to safeguard critical infrastructure are attributed to the demand for anti-drone.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=177013645
Browse in-depth TOC on “Anti-Drone Market” 178 – Tables61 – Figures253 – Pages
Anti-Drone Market Report Scope:
Report Coverage
Details
Market Revenue in 2024
$ 2.16 billion
Estimated Value by 2029
$ 7.05 billion
Growth Rate
Poised to grow at a CAGR of 26.7%
Market Size Available for
2020–2029
Forecast Period
2024–2029
Forecast Units
Value (USD Million/Billion)
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
By System Type, Application, Platform type, Vertical, and Region
Geographies Covered
North America, Europe, Asia Pacific, and Rest of World
Key Market Challenge
Vulnerability to hacking
Key Market Opportunities
Emphasis on improving unmanned aircraft systems technology
Key Market Drivers
Growing number of illicit activities
By System Type: Hybrid systems to account for the larger market share in the forecasted year.
The hybrid segment accounted for the largest share of the anti-drone market in 2029. The trends of integrating multiple anti-drone technologies are rising since they are most effective in detecting, tracking, and neutralizing drone threats. These systems merge electronic, kinetic, and lasers, providing a comprehensive defense solution against UAVs. Hybrid systems use electronic, kinetic, and laser-based countermeasures to offer optimum protection against drones. These systems are designed to detect, track, identify, categorize, and mitigate drones at operational wide ranges ranging from a few km up to tens of km.
By Platform: The ground-based segment accounted for the largest market share in the forecast year.
The ground-based segment will hold a major share of the anti-drone market in 2029. Many ground-based anti-drone systems use several electronic technologies, such as radar, IR sensors, acoustic systems, and RF & GNSS jammers. MESA radar solutions are used mostly for counter-UAS purposes, protecting critical infrastructure, military camps, and other security-sensitive sites from unauthorized drones. One such solution is EchoGuard, a ground-based airspace management solution that contains a software-defined 3D radar that can be specific to the site. This system can identify single or multiple off-chance drones, including swarms in unauthorized areas. They provide accurate and sustained airspace surveillance for the field of view (FOV) they are configured, and both human and AI-monitored visual checks. The system can be easily transported and integrated directly with the command-and-control centers or another identification sensor for portable use, and multiple units of the system can be combined to cover vast areas or lengths of borders. Major providers of ground-based counter-drone systems include companies like EchoDyne Corporation, DeTect, Meteksan Defense, and WhiteFox Defense. Acoustics-based Discovair G2 utilizes patented microphone arrays. With 128 interconnected microphone elements, the Discovair sensor units can establish azimuth and elevation to the target in real-time using advanced digital signal processing.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=177013645
By Region: Americas are expected to hold the largest share of the anti-drone market during the forecast period.
Americas is expected to capture the largest share in the anti-drone industry during the forecast period. The growth can be attributed to protecting crucial infrastructure in the region. Governments, particularly in the US, invest in anti-drone systems for military bases, borders, and critical infrastructure. For Instance, in April 2023, RTX secured a USD 237 million contract from the US Army to provide Ku-band Radio Frequency Sensors (KuRFS) and Coyote effectors. These systems are designed to detect and neutralize unmanned aircraft systems (UAS). The contract includes stationary and mobile systems and a specified quantity of effectors, all aimed at enhancing the Army’s operations within the US Central Command region.
Key Players-
The key companies offering anti-drone companies include RTX (US), Lockheed Martin Corporation (US), Leonardo S.p.A. (Italy), Thales (France), and IAI (Israel).
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=177013645
Browse Adjacent Market: Semiconductor and Electronics Market Research Reports &Consulting
Related Reports: 
Drone Sensor Market Size, Share, Industry Growth & Trends by Sensor Type, Platform (VTOL Type, Fixed Wing Type, Hybrid Type), Application (Navigation, Collision Detection & Avoidance, Data Acquisition, Motion Detection, Power Monitoring), End Users and Region – Global Forecast to 2029
Smart Agriculture Market Size, Share, Statistics and Industry Growth Analysis Report by Offering (Hardware, Software, Services), Agriculture Type, Farm Size (Large, Medium, Small), Application (Precision Farming, Livestock Monitoring) and Region (America, Europe, Asia Pacific, Row) – Global Forecast to 2028
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact: Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected] Our Web Site: https://www.marketsandmarkets.com/Research Insight: https://www.marketsandmarkets.com/ResearchInsight/anti-drone-market.aspContent Source: https://www.marketsandmarkets.com/PressReleases/anti-drone.asp
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/anti-drone-market-worth-7-05-billion-by-2029—exclusive-report-by-marketsandmarkets-302260893.html

Continue Reading

Artificial Intelligence

CluePoints Launches Medical & Safety Review (MSR) Software to Revolutionize Clinical Data Review

Published

on

cluepoints-launches-medical-&-safety-review-(msr)-software-to-revolutionize-clinical-data-review

CluePoints furthers its commitment to delivering innovative solutions that enhance clinical trial efficiency with this latest addition to its enterprise software platform.
KING OF PRUSSIA, Pa., Sept. 27, 2024 /PRNewswire/ — CluePoints continues to transform clinical trial review and leverage its industry-leading software to enhance the interrogation, analysis and presentation of data with the launch of its latest application, Medical & Safety Review (MSR).

The tool simplifies and streamlines the medical analysis of study data through user-friendly dashboards, data manipulation and cleaning, query management and full transparency over the data history. This not only improves efficiency and communication in medical oversight, but also elevates patient safety, differentiating MSR as a smarter and unique solution.
Designed by, and for Medical and Safety Reviewers, MSR converts the manual analysis of patient outcomes, which can be prone to inefficiency and error, into an accurate, efficient process. MSR tackles time-consuming study preparation for specific visualizations by featuring a comprehensive standard visualization library as well as the ability to copy and reuse dashboards across different studies, enabling the identification of outlying values, change tracking, and improved communication for smarter clinical trials.
Other benefits of MSR include:
Enhanced medical review efficiency and reduced human errors via automated checksReduced time spent by clinical and data management teams in reviewing dataImproved collaboration with integrated review workflows across departmentsEnsured record quality and accountability with comprehensive change trackingDriving faster decision making with the proactive detection of trends and safety issuesEnsuring regulatory compliance with rule-based detection and user assignmentsAndy Cooper, Chief Executive Officer at CluePoints, commented, “We are thrilled to announce the launch of Medical & Safety Review to our growing product offerings. MSR is the latest application addition to the CluePoints platform, which includes products such as Risk-Based Quality Management (RBQM) and our Site Profile & Oversight Tool (SPOT). Together, they provide a comprehensive approach to clinical trial optimization, enhancing data integrity, ensuring regulatory compliance, and accelerating drug development. The creation of MSR ensures a more streamlined review process while prioritizing patient safety at every step and empowers medical teams to swiftly identify outliers, track data changes, and improve communication.”
To learn more about CluePoints’ award-winning solutions, please visit www.cluepoints.com
About CluePoints
CluePoints is the premier Risk-Based Quality Management (RBQM) and Data Quality Oversight Software provider. We are leveraging the potential of Artificial Intelligence using Advanced Statistics and Machine Learning to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA, EMA, and ICH E6 (R2), CluePoints is deployed to support central and on-site monitoring, medical review, quality risk management and to drive a holistic Risk-Based strategy in all trials. Coupled with thought leadership and consulting expertise to aid pre-study risk assessment, identification of risk controls and solution implementation, you now have everything you need to adhere with global regulatory guidance. The result is positive clinical development outcomes, increased operational efficiency, lower costs and reduced regulatory submission risk as part of the industry paradigm shift to RBQM.
 

View original content:https://www.prnewswire.co.uk/news-releases/cluepoints-launches-medical–safety-review-msr-software-to-revolutionize-clinical-data-review-302260936.html

Continue Reading

Trending